Fluconazole Treatment for AIDS-Associated Cryptococcal Meningitis
Author Information
Author(s): C. F. Schaars, G. A. Meintjes, C. Morroni, F. A. Post, G. Maartens
Primary Institution: University of Cape Town
Hypothesis
Does the use of standard-dose fluconazole improve outcomes for patients with AIDS-associated cryptococcal meningitis compared to low-dose fluconazole?
Conclusion
The outcome of AIDS-associated cryptococcal meningitis is similar with low or standard doses of fluconazole, and early mortality remains high.
Supporting Evidence
- Following the fluconazole donation, fewer patients received no antifungal treatment (5% vs 19%).
- More patients received standard-dose fluconazole (90% vs 6%).
- In-hospital mortality was 25%, with impaired consciousness and no antifungal treatment being independent predictors of mortality.
- Median survival was 76 days for low-dose and 82 days for standard-dose fluconazole.
Takeaway
This study looked at how well patients with a serious brain infection did when treated with different doses of a medicine called fluconazole. It found that using a higher dose didn't make things better than using a lower dose.
Methodology
Retrospective chart review of adult patients before and after the fluconazole donation.
Potential Biases
Potential bias due to retrospective design and selection of patients based on prognosis.
Limitations
The study is retrospective, and some groups were too small for meaningful conclusions.
Participant Demographics
Most patients were black Africans, with 78% having cryptococcal meningitis as their initial AIDS-defining illness.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website